IXICO signs expanded scope to current contract with top 10 biopharmaceutical company

Increasing contract value by $2.4m over the remaining term

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces that it has signed an expanded scope to a current contract with a top 10 biopharmaceutical company. Additional services will be provided, increasing the value of the contract by $2.4m over the remaining 6-year term of the agreement. As a result, the contract value has increased from $2.7m to $5.1m.

The expanded scope will see IXICO providing additional imaging services, to a significantly higher number of patients, and an increased number of participating international study sites.

Giulio Cerroni, Chief Executive of IXICO, said: “I am delighted that our client has decided to expand our involvement in this important study. We value the strength of our relationships with biopharmaceutical companies and our ability to provide them with important insights that support their efforts to bring new therapies to market. This latest increase in scope demonstrates IXICO’s ability to efficiently scale operations and adapt to changing requirements as global clinical studies progress.”

PRESS RELEASE
By |2018-12-04T07:17:07+00:004 December 2018|Contracts|